NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Treatment with tumour necrosis factor inhibitors may slow disease progression in patients with axSpA

By Mindo - 16th Jul 2021

Priscilla Lynch provides a round-up of some of the most topical research presented at this year’s EULAR Congress, which took place virtually from 2-5 June

Sacroiliitis is linked to the disease axial spondyloarthritis (axSpA) and visible on X-ray. Observational cohort studies have shown that there is low, but still detectable progression in radiographic sacroiliitis, which might also have an impact on the function in patients with axSpA. Recent data show that tumour necrosis factor inhibitors (TNFi) might slow spinal progression when started earlier and taken for longer. However, the question of whether they also have such an effect on radiographic progression in sacroiliac joints is still unclear.

Murat Torgutalp and colleagues investigated the longitudinal association between radiographic sacroiliitis progression and treatment with TNFi in patients with early axSpA in a long-term inception cohort. The results were shared in an oral session at the 2021 EULAR Congress. Based on the availability of at least two sets of sacroiliac joint (SIJ) radiographs, 166 patients with non-radiographic axial spondyloarthritis (nr-axSpA), and 135 with radiographic (r-axSpA), from the German Spondyloarthritis Inception Cohort (GESPIC) were included in the analysis.

Observational cohort studies have shown that there is low, but still detectable progression in radiographic sacroiliitis

Two trained and calibrated central readers scored the radiographs, and if both scored an image as definite radiographic sacroiliitis, the patient was classified as having r-axSpA. The association between previous and current TNFi use, and change in the sacroiliitis sum score over two years was analysed.

At baseline, nine (3.0 per cent) patients were treated with a TNFi, and 87 (28.9 per cent) patients received at least one TNFi during the entire follow-up period. While receiving 12 or more months of TNFi in the previous interval was associated with lower progression of the sacroiliitis sum score compared to not receiving TNFi in the previous interval, this was not the case in patients who received TNFi for longer than 12 months in the current two-year interval.

The significant association between TNFi use for longer than 12 months in the previous interval and progression in the sacroiliitis sum score were confirmed in the adjusted analysis. In addition, a similar trend for the beneficial effects was observed in different models, which included other treatment definitions with TNFi in the previous two-year interval.
The authors concluded that TNFi treatment was associated with slowing radiographic sacroiliitis progression in people with axSpA. This effect became evident two-to-four years after treatment initiation.

Leave a Reply

Latest Issue
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read